Clinical Trials
6
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
- Conditions
- Osteogenesis Imperfecta (OI)
- Interventions
- Other: Placebo
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Angitia Incorporated Limited
- Target Recruit Count
- 80
- Registration Number
- NCT07062588
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Angitia Biopharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT06577935
- Locations
- 🇦🇷
Centro Médico Arsema, Buenos Aires, Argentina
🇦🇷Centro Médico Dra Laura Maffei e Investigación Cliínica Aplicada, Buenos Aires, Argentina
🇦🇷Consultorio de Investigacion Clinica EMO SRL, Buenos Aires, Argentina
A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Angitia Biopharmaceuticals
- Target Recruit Count
- 400
- Registration Number
- NCT06115512
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Angitia Incorporated Limited
- Target Recruit Count
- 72
- Registration Number
- NCT06086613
- Locations
- 🇺🇸
Orange County Research Center, Lake Forest, California, United States
A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Angitia Biopharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05574543
- Locations
- 🇨🇳
Beijing Jishuitan Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
- Prev
- 1
- 2
- Next
News
AGA111 Shows Promising Results in Spinal Fusion Clinical Trial, Advances to Phase 3
Angitia Biopharmaceuticals' Phase 1/2 study demonstrated that AGA111, a recombinant human bone morphogenetic protein 6, achieved faster radiographic fusion and higher fusion success rates compared to placebo in spinal fusion procedures.
Angitia Biopharmaceuticals Doses First Patient in Phase 2 Trial of AGA2118 for Osteoporosis
Angitia Biopharmaceuticals has initiated a Phase 2 clinical trial (ARTEMIS) of AGA2118 for treating postmenopausal osteoporosis.
Angitia Biopharmaceuticals Doses First Patient in Phase 2 Trial of AGA2118 for Osteoporosis
Angitia Biopharmaceuticals has dosed the first patient in its Phase 2 ARTEMIS trial evaluating AGA2118 for postmenopausal osteoporosis.